Document text
Principal Investigator: PAMELA L. Lutsey
Organization: UNIVERSITY OF MINNESOTA
Fiscal Year: 2024
Award: $104,141
Funding agency: National Heart Lung and Blood Institute
SUMMARY
This application will provide the Principal Investigator, Dr. Pamela Lutsey, with protected time and other
support to 1) accelerate a successful record of mentoring junior clinical investigators and graduate students
engaged in cardiovascular disease (CVD) patient-oriented research (POR), 2) obtain additional training in
pharmacoepidemiology, -omics and mentoring best practices and 3) advance her ongoing CVD
pharmacoepidemiology research program. Pharmaceuticals play a crucial role in the prevention and treatment
of CVD and other conditions. To improve the effectiveness of pharmacologic interventions on CVD outcomes,
we need junior clinical investigators conducting POR who have rigorous training and mentorship in the areas
of pharmacoepidemiology, clinical epidemiology of CVD, translational research methods and the use of
complex data sources. An expert in these areas, the candidate, Dr. Lutsey, proposes to apply K24 funds
toward the mentorship of POR scholars at the University of Minnesota who are committed to a research
career that will reduce the burden of CVD in the population through building rigorous evidence regarding how
to optimize use of pharmaceuticals in order to prevent CVD in at-risk populations and reduce risk of
recurrence among individuals with CVD. Aim 1 involves conducting pharmacoepidemiology POR comparative
effectiveness research to prevent CVD in at-risk populations and improve the outcomes among CVD
survivors. State-of-the-art pharmacoepidemiologic techniques will be applied to large administrative data
sources, specifically MarketScan and the Medicare 20% sample. Aim 2 will harness rich data from deeply
phenotyped cohorts to understand behavioral characteristics that influence the effectiveness of medications,
and glean added understanding of the physiologic mechanisms through which pharmacotherapies act. These
analyses will use data from the Atherosclerosis Risk in Communities (ARIC) study and the Multi-Ethnic Study
of Atherosclerosis (MESA). Findings from the proposed Aims will advance understanding of the role of specific
pharmacologic treatment strategies on CVD risk, and have potential to directly impact clinical practice,
reinforcing or leading to reconsideration of existing clinical guidelines. This proposal is structured to allow
trainees the flexibility to pursue their own hypotheses, motivated by their clinical experiences and interests.
With support from this K24, Dr. Lutsey plans to expand the breadth of her POR research activities, recruit new
junior clinical scholars into POR, and prepare them to make major scientific advances and launch their own
independent research careers.
Terms: <21+ years old><65 and older><65 or older><65 years of age and older><65 years of age or more><65 years of age or older><65+ years><65+ years old><> 65 years><Acceleration><Address><Adult><Adult Human><Adverse Experience><Adverse event><Aged 65 and Over><Anticoagulant Agents><Anticoagulant Drugs><Anticoagulants><Area><Atherosclerosis Risk in Communities><Atrial Fibrillation><Auricular Fibrillation><Behavioral><Cancer Patient><Cancers><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Characteristics><Clinical><Clinical Investigator><Comparative Effectiveness Research><Complex><Data><Data Sources><Disease Outcome><Drug Interactions><Drug Therapy><Drug usage><Drugs><Effectiveness><Elderly><Environment><Ethnic Origin><Ethnicity><Funding><Genes><Glean><Groups at risk><Guidelines><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Heart Vascular><Heart failure><Hypertension><Individual><Intervention><Intervention Strategies><Investigators><K24 Award><Kidney Diseases><Knowledge><Lead><Learning><Malignant Neoplasms><Malignant Tumor><Manuscripts><Medicare><Medication><Mentors><Mentorship><Methodology><Methods><Mid-Career Clinical Scientist Award (K24)><Minnesota><Multi-Ethnic Study of Atherosclerosis><Nephropathy><Oral><Outcome><Participant><Patients><Pb element><People at risk><Persons at risk><Pharmaceutical Agent><Pharmaceutical Epidemiology><Pharmaceutical Preparations><Pharmaceuticals><Pharmacoepidemiology><Pharmacologic Substance><Pharmacological Substance><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiologic><Physiological><Play><Polypharmacy><Population><Populations at Risk><Prevalence><Prevention><Principal Investigator><Proteomics><Publishing><QOC><Quality of Care><Race><Races><Randomized, Controlled Trials><Recurrence><Recurrent><Renal Disease><Research><Research Activity><Research Methodology><Research Methods><Research Personnel><Researchers><Risk Reduction><Role><Sample Size><Sampling><Scientific Advances and Accomplishments><Structure><Supervision><Survivors><Techniques><Testing><Time><Title 18><Training><Translational Research><Translational Science><Universities><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><above age 65><adulthood><advanced age><adverse consequence><adverse outcome><after age 65><age 65 and greater><age 65 and older><age 65 or older><age > 65><age of 65 years onward><aged 65 and greater><aged 65+><aged ≥65><assess effectiveness><blood thinner><burden of disease><burden of illness><cardiac failure><cardiovascular disease epidemiology><cardiovascular disease risk><cardiovascular disorder><cardiovascular disorder epidemiology><cardiovascular disorder risk><cardiovascular epidemiology><career><career development><circulatory system><clinical epidemiology><clinical practice><clinical significance><clinically significant><cohort><comparative effectiveness><complex data><determine effectiveness><diabetes control><diabetes mellitus control><disease burden><drug adherence><drug compliance><drug epidemiology><drug treatment><drug use><drug/agent><effectiveness assessment><effectiveness evaluation><effectiveness research><evaluate effectiveness><examine effectiveness><experience><flexibility><flexible><geriatric><graduate student><health insurance for disabled><health literacy><heavy metal Pb><heavy metal lead><high blood pressure><human old age (65+)><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><improved><improved outcome><interest><interventional strategy><kidney disorder><malignancy><medication adherence><medication compliance><multimorbidity><multiple chronic conditions><neoplasm/cancer><novel><old age><older adult><older adulthood><over 65 years><patient centered><patient oriented><patient oriented research><patient oriented study><patient population><pharmaceutical><pharmacoepidemiologic><pharmacoepidemiological><pharmacologic><post-market><prevent><preventing><programs><prospective><pulmonary arterial hypertension><pulmonary artery hypertension><racial><racial background><racial origin><randomized control trial><recruit><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><renal disorder><research and methods><response><risk-reducing><rural disparities><scientific accomplishments><scientific advances><senior citizen><skill acquisition><skill development><social role><student engagement><student motivation><student participation><thrombopoiesis inhibitor><training opportunity><translation research><translational investigation><treatment strategy><venous thromboembolism><≥65 years>